


**APC/Fire™ 750 anti-human CD223 (LAG-3)**

**Catalog # /** 2446650 / 100 tests  
**Size:** 2446645 / 25 tests  
**Clone:** 11C3C65  
**Isotype:** Mouse IgG1, κ  
**Immunogen:** Human LAG-3 transfected cells.  
**Reactivity:** Human  
**Preparation:** The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 under optimal conditions.  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).  
**Workshop Number:** 750 under optimal conditions.  
**Concentration:** Lot-specific



CD3/CD28/IL-2 stimulated (three days) peripheral blood mononuclear cells were stained with CD8 FITC and CD223 (LAG-3, clone 11C3C65) APC Fire™ 750 (left) or mouse IgG1, κ APC Fire™ 750 isotype control (right).

**Applications:**


**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

\* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

**Application Notes:** The staining of clone 11C3C65 cannot be blocked by clone 7H2C65, which is another anti-human CD223 (LAG-3) antibody.

- Application References:**
1. Bradstock KF, *et al.* 1980. *J. Natl. Cancer Inst.* 65:33.
  2. Csiba A, *et al.* 1984. *Br. J. Cancer* 50:699.
  3. Tchilian EZ, *et al.* 2001. *J. Immunol.* 166:1308.
  4. Lee MS, *et al.* 2004. *Int. Immunol.* 16:1109.



**Description:** CD223, also known as LAG-3, is a 70 kD type I transmembrane glycoprotein that is involved in T-cell signaling. Similar to CD4, CD223 binds MHC class II, but with a higher affinity. CD223 negatively regulates T-cell activation. It is expressed by activated T-cells and natural killer cells (NKs), as well as regulatory T-cells. It is transiently expressed on the surface of activated T-cells in acute conditions but high expression is maintained under tolerizing conditions. CD223 deficiency results in reduced tumor growth. CD223 and PD-1 can act in synergy and reverse exhausted phenotypes, improve tumor rejection, and control viral load.

**Antigen**  
**References:**

1. Castelli C, *et al.* 2014. *Oncoimmunology*. 3(11):e967146.
2. Poirier N, *et al.* 2011. *Clin. Exp. Immunol.* 164:265.
3. Juno JA, *et al.* 2015. *Retrovirology*. 12:17.
4. Casati C, *et al.* 2006. *Cancer Res.* 66:4450.